Nanxin Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nanxin Gong has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Chunlei Wang
State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and College of Pharmacy, Nankai University, Tianjin, PR China
2 shared publicationsAncheng Chen
Shanghai Zelixir Biotech Company Ltd, Shanghai, PR China
1 shared publicationBaoxin Duan
State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and College of Pharmacy, Nankai University, Tianjin, PR China
1 shared publication- Cuizhu Zhang
College of Life Science, Nankai University, Tianjin, China; Nankai International Advanced Research Institute (Shenzhen Futian), Nankai University, Shenzhen, China
1 shared publication - Du-Qiang Luo
College of Life Sciences, Institute of Life Science and Green Development and Hebei Innovation Center for Bioengineering and Biotechnology, Hebei University, Baoding, China
1 shared publication Feilong Zhou
State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and College of Pharmacy, Nankai University, Tianjin, PR China
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1) , 729
Structural basis of Fumosorinone-mediated allosteric inhibition of PTP1B for cancer immunotherapy
Protein Tyrosine Phosphatase 1B (PTP1B) is a key immune regulator in cancer and an attractive immunotherapy target, yet progress is limited by the lack of selective inhibitors. Here, we identify Fumosorinone (FU), a natural product from Isaria fumosorosea , as a potent and selective allosteric inhibitor of PTP1B. In a murine colon tumor model, FU enhances anti-tumor immunity by reshaping the microenvironment, strengthening CD8⁺ T-cell responses, and promoting M1-like macrophage polarization. Enzymatic and biophysical analyses confirm its potency and direct engagement with PTP1B. A co-crystal structure defines a previously uncharacterized allosteric pocket that stabilizes the inactive state of the enzyme. This pocket is poorly conserved across the PTP family, consistent with minimal activity toward related phosphatases except TCPTP. Guided by this insight, virtual screening identifies additional inhibitors. These findings provide a structural basis for selective PTP1B targeting and support future immunotherapy development and rational drug discovery efforts.
- 28 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1) , 729
Open AccessStructural basis of Fumosorinone-mediated allosteric inhibition of PTP1B for cancer immunotherapy
Protein Tyrosine Phosphatase 1B (PTP1B) is a key immune regulator in cancer and an attractive immunotherapy target, yet progress is limited by the lack of selective inhibitors. Here, we identify Fumosorinone (FU), a natural product from Isaria fumosorosea , as a potent and selective allosteric inhibitor of PTP1B. In a murine colon tumor model, FU enhances anti-tumor immunity by reshaping the microenvironment, strengthening CD8⁺ T-cell responses, and promoting M1-like macrophage polarization. Enzymatic and biophysical analyses confirm its potency and direct engagement with PTP1B. A co-crystal structure defines a previously uncharacterized allosteric pocket that stabilizes the inactive state of the enzyme. This pocket is poorly conserved across the PTP family, consistent with minimal activity toward related phosphatases except TCPTP. Guided by this insight, virtual screening identifies additional inhibitors. These findings provide a structural basis for selective PTP1B targeting and support future immunotherapy development and rational drug discovery efforts.
- Open Access
- 10 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Chimeras co-targeting antigens and FcγRIIb trigger degradation of extracellular soluble proteins and pathological aggregates
While the clinical utility of conventional antibody therapies is undeniable, their therapeutic potential is often constrained high antigen loads and the recycling of antibody-antigen complexes via neonatal Fc receptor (FcRn). Here, we present a platform, based on a design similar to bispecific antibodies, FcγRIIb-Targeting Chimeras (FcRTAC). These constructs recognise antigens with one arm and bind FcγRIIb with the other arm to harness the unique endocytic properties of FcγRIIb to direct the recognized pathogenic antigens to lysosomes for irreversible degradation. The FcRTAC platform demonstrates broad therapeutic potential across multiple disease-relevant targets, including IgE, proprotein convertase subtilisin/kexin type 9 (PCSK9) and amyloid-β (Aβ). Notably, a single intravenous administration of blood brain barrier (BBB)-penetrating adeno-associated viral vector (AAV) encoding an Aβ-targeting FcRTAC construct achieves sustained therapeutic effects, establishing proof-of-concept for AAV-mediated delivery of an Aβ degrader as a strategy for Alzheimer’s disease treatment. Our comprehensive investigation of binding properties of FcRTACs reveals critical molecular determinants of function and enables development of optimized engineering approaches. In summary, our approach represents a versatile therapeutic platform for treating diverse diseases ranging from autoimmune disorders to neurodegenerative conditions, while simultaneously serving as a user-friendly, plug-and-play research tool for extracellular protein knockout in basic biological research.
- 10 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessChimeras co-targeting antigens and FcγRIIb trigger degradation of extracellular soluble proteins and pathological aggregates
While the clinical utility of conventional antibody therapies is undeniable, their therapeutic potential is often constrained high antigen loads and the recycling of antibody-antigen complexes via neonatal Fc receptor (FcRn). Here, we present a platform, based on a design similar to bispecific antibodies, FcγRIIb-Targeting Chimeras (FcRTAC). These constructs recognise antigens with one arm and bind FcγRIIb with the other arm to harness the unique endocytic properties of FcγRIIb to direct the recognized pathogenic antigens to lysosomes for irreversible degradation. The FcRTAC platform demonstrates broad therapeutic potential across multiple disease-relevant targets, including IgE, proprotein convertase subtilisin/kexin type 9 (PCSK9) and amyloid-β (Aβ). Notably, a single intravenous administration of blood brain barrier (BBB)-penetrating adeno-associated viral vector (AAV) encoding an Aβ-targeting FcRTAC construct achieves sustained therapeutic effects, establishing proof-of-concept for AAV-mediated delivery of an Aβ degrader as a strategy for Alzheimer’s disease treatment. Our comprehensive investigation of binding properties of FcRTACs reveals critical molecular determinants of function and enables development of optimized engineering approaches. In summary, our approach represents a versatile therapeutic platform for treating diverse diseases ranging from autoimmune disorders to neurodegenerative conditions, while simultaneously serving as a user-friendly, plug-and-play research tool for extracellular protein knockout in basic biological research.